A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy
Open accessAbstract
68Ga-gozetotide (68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with 177Lu-vipivotide tetraxetan (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A substudy required by the U.S. Food and Drug Administration showed that the VISION eligibility read rules were readily learned and had good reproducibility.
“A substudy required by the U.S. Food and Drug Administration showed that the VISION eligibility read rules used were readily learned and had good reproducibility (11).”
Visual assessment of 68Ga-PSMA-11 PET/CT scans according to the VISION trial read rules is an accurate and straightforward means of identifying candidates for 177Lu-PSMA-617 treatment.
“Visual assessment of 68Ga-PSMA-11 PET/CT scans according to the VISION trial read rules is an accurate and straightforward means of identifying candidates for 177Lu-PSMA-617 treatment (11).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 16 · Cited by 22
- Authors
- Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., Brackman, M., Kpamegan, E., Ghebremariam, S., Benson, T., Catafau, A. M., & Kendi, A. T.
- Affiliations
- University of Arizona (US)
- Brown University (US)
- Northwestern University (US)
- Dartmouth College (US)
- Radboud University Medical Center (NL)
- Technical University of Munich (DE)
- Essen University Hospital (DE)
- The University of Melbourne (AU)
- Universitätsmedizin Rostock (DE)
- Novartis (United States) (US)
- Mayo Clinic (US)
- Corresponding author
- Kuo, Phillip H.
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2023-05-25
- Volume
- 64
- Issue
- 8
- Pages
- 1259-1265
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC10394308
- OpenAlex
- W4378214169
- Cited by
- 22
- References
- 16
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 10 · 2023: 2
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Journal of Nuclear Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Amgen
- AstraZeneca
- Bayer
- Sanofi
- Advanced Accelerator Applications
- Eisai
- Astellas Pharma
- Ipsen
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- 68Ga-PSMA-11 PET/CT, 177Lu-PSMA-617, radioligand therapy, castration-resistant prostate cancer, metastatic prostate cancer, inter-reader variability, patient eligibility, visual interpretation, reader agreement, Fleiss' kappa
- MeSH terms
- Positron Emission Tomography Computed Tomography, Dipeptides, Gallium Isotopes, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring, Humans, Male, Prostatic Neoplasms, Retrospective Studies, Reproducibility of Results, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review